Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
Lieske H SchrijverThea M MooijAnouk PijpeGabe S SonkeMarian J E MouritsNadine AndrieuAntonis C AntoniouDouglas F EastonChristoph EngelDavid GoldgarIsabelle DurotKarin KastJonathan BeesleyHåkan OlssonKelly-Anne PhillipsMary Beth TerryJohn L HopperFlora E van LeeuwenMatti A RookusPublished in: Journal of the National Cancer Institute (2022)
Although COCP use in BRCA1 and BRCA2 mutation carriers initially increases breast, ovarian, and endometrial cancer risk, it strongly decreases lifetime cancer risk. Risk-reducing bilateral salpingo-oophorectomy and menopausal hormone therapy use appear to counteract the long-term COCP-benefit.